Treatment of axial spondyloarthritis patients with biologic disease-modifying anti-rheumatic drugs in 2022 - data from the Romanian Registry of Rheumatic Diseases

Objective. The objective of this cross-sectional study was to analyze data available in the Romanian Registry of Rheumatic Diseases (RRBR) in 2022 for axial spondyloarthritis (axSpA) patients treated with biologic disease modifying anti-rheumatic drugs (bDMARDs). Methods. From the RRBR electronic da...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:Romanian Journal of Rheumatology
المؤلفون الرئيسيون: Laura Muntean, Razvan Ionescu, Corina Mogosan, Maria-Magdalena Tamas, Claudiu C. Popescu, Elena Rezus, Razvan-Constantin Ionitescu, Ana Maria Ramazan, Andrei Eugen Martin, Catalin Codreanu
التنسيق: مقال
اللغة:الإنجليزية
منشور في: Amaltea Medical Publishing House 2023-12-01
الموضوعات:
axial spondyloarthritis
biologics
romanian registry of rheumatic diseases
الوصول للمادة أونلاين:https://rjr.com.ro/articles/2023.4/RJR_2023_4_Art-04.pdf

الانترنت

https://rjr.com.ro/articles/2023.4/RJR_2023_4_Art-04.pdf

مواد مشابهة